Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
11.13
+0.13 (1.18%)
At close: May 8, 2026, 4:00 PM EDT
11.20
+0.07 (0.63%)
After-hours: May 8, 2026, 7:59 PM EDT
Zevra Therapeutics Revenue
Zevra Therapeutics had revenue of $36.22M in the quarter ending March 31, 2026, with 77.54% growth. This brings the company's revenue in the last twelve months to $122.29M, up 201.29% year-over-year. In the year 2025, Zevra Therapeutics had annual revenue of $106.47M with 350.91% growth.
Revenue (ttm)
$122.29M
Revenue Growth
+201.29%
P/S Ratio
5.38
Revenue / Employee
$2,004,738
Employees
61
Market Cap
657.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 106.47M | 82.86M | 350.91% |
| Dec 31, 2024 | 23.61M | -3.85M | -14.02% |
| Dec 31, 2023 | 27.46M | 17.00M | 162.58% |
| Dec 31, 2022 | 10.46M | -18.19M | -63.50% |
| Dec 31, 2021 | 28.65M | 15.36M | 115.61% |
| Dec 31, 2020 | 13.29M | 449.00K | 3.50% |
| Dec 31, 2019 | 12.84M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 311.71M |
| Arvinas | 262.60M |
| Sutro Biopharma | 102.48M |
| Crescent Biopharma | 11.88M |
| Aclaris Therapeutics | 8.37M |
ZVRA News
- 1 day ago - Zevra Therapeutics price target raised to $25 from $23 at Guggenheim - TheFly
- 3 days ago - Zevra Therapeutics reports Q1 EPS 60c, consensus 8c - TheFly
- 3 days ago - Zevra Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 3 days ago - Zevra Reports First Quarter 2026 Financial Results and Corporate Update - GlobeNewsWire
- 7 weeks ago - Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Zevra Therapeutics sells SDX portfolio to Commave for $50M - TheFly
- 7 weeks ago - Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million - GlobeNewsWire
- 7 weeks ago - Zevra Therapeutics initiated with a Buy at BTIG - TheFly